{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:07:48Z","timestamp":1794935268530,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Quality of life (QoL) in patients with Parkinson\u2019s disease (PD) is increasingly used as an efficacy outcome in clinical studies of PD to evaluate the impact of treatment from the patient\u2019s perspective. Studies demonstrating the treatment effect of pramipexole on QoL remain inconclusive. This study aims to evaluate the effect of pramipexole on QoL in patients with PD by conducting a systematic review and meta-analysis of existing clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature search of PubMed, Embase and the Cochrane Library was performed from inception to 30 April 2022 to identify randomised, placebo-controlled trials of patients with idiopathic PD receiving pramipexole, who reported a change from baseline in their QoL as measured by the 39-item Parkinson\u2019s Disease Questionnaire (PDQ-39). Risk of bias was independently assessed by two reviewers using the Cochrane Collaboration\u2019s tool for bias assessment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 80 eligible articles screened, six trials consisting of at least 2000 patients with early or advanced PD were included. From the synthesis of all six selected trials, a significant mean change from baseline in the PDQ-39 total score of \u20132.49 (95% CI, \u20133.43 to \u20131.54;<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) was observed with pramipexole compared with placebo. A trend toward improvement in QoL was consistently observed among patients who received optimal doses of pramipexole (\u2265\u200980% of the study population on 1.5\u00a0mg dosage), regardless of disease severity (advanced versus early) or baseline QoL levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This meta-analysis provides evidence for the potential treatment benefit of pramipexole in improving QoL in patients with PD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-022-02830-y","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:04:34Z","timestamp":1661418274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy of pramipexole on quality of life in patients with Parkinson\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Tao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiruo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"2830_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386:896\u2013912.","journal-title":"Lancet"},{"issue":"Suppl 7","key":"2830_CR2","first-page":"Vii2","volume":"253","author":"W Poewe","year":"2006","unstructured":"Poewe W. The natural history of Parkinson\u2019s disease. J Neurol. 2006;253(Suppl 7):Vii2-6.","journal-title":"J Neurol."},{"key":"2830_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/mds.26885","volume":"32","author":"P Martinez-Martin","year":"2017","unstructured":"Martinez-Martin P. What is quality of life and how do we measure it? relevance to Parkinson\u2019s disease and movement disorders. Mov Disord. 2017;32:382\u201392.","journal-title":"Mov Disord"},{"key":"2830_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.parkreldis.2018.03.027","volume":"52","author":"M Skorvanek","year":"2018","unstructured":"Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, et al. Relationship between the MDS-UPDRS and quality of life: a large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018;52:83\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"2830_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40263-015-0247-x","volume":"29","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Kurtis MM. Impact of pharmacotherapy on quality of life in patients with Parkinson\u2019s disease. CNS Drugs. 2015;29:397\u2013413.","journal-title":"CNS Drugs"},{"key":"2830_CR6","first-page":"375","volume":"5","author":"JA Opara","year":"2012","unstructured":"Opara JA, Brola W, Leonardi M, B\u0142aszczyk B. Quality of life in Parkinson\u2019s disease. J Med Life. 2012;5:375\u201381.","journal-title":"J Med Life"},{"key":"2830_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cns.13549","volume":"27","author":"N Zhao","year":"2021","unstructured":"Zhao N, Yang Y, Zhang L, Zhang Q, Balbuena L, Ungvari GS, et al. Quality of life in Parkinson\u2019s disease: a systematic review and meta-analysis of comparative studies. CNS Neurosci Ther. 2021;27:270\u20139. https:\/\/doi.org\/10.1111\/cns.13549.","journal-title":"CNS Neurosci Ther"},{"key":"2830_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33:1248\u201366.","journal-title":"Mov Disord"},{"issue":"Suppl 4","key":"2830_CR9","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S1353-8020(09)70837-5","volume":"15","author":"P Martinez-Martin","year":"2009","unstructured":"Martinez-Martin P, Kurtis MM. Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. Parkinsonism Relat Disord. 2009;15(Suppl 4):S58-64.","journal-title":"Parkinsonism Relat Disord"},{"key":"2830_CR10","unstructured":"Pramipexole (Sifrol\u00ae prolonged-release tablets): summary of product characteristics. European Medicines Agency; 2007."},{"key":"2830_CR11","unstructured":"Mirapex\u00ae prescribing information. Boehringer Ingelheim; 2021."},{"key":"2830_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2165\/00023210-200822070-00003","volume":"22","author":"DA Gallagher","year":"2008","unstructured":"Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson\u2019s disease. CNS Drugs. 2008;22:563\u201386.","journal-title":"CNS Drugs"},{"key":"2830_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14737167.2021.1841638","volume":"21","author":"A Berardi","year":"2021","unstructured":"Berardi A, Regoli E, Tofani M, Valente D, Fabbrini G, Fabbrini A, et al. Tools to assess the quality of life in patients with Parkinson\u2019s disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21:55\u201368.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"Suppl 1","key":"2830_CR14","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1007\/PL00007730","volume":"245","author":"V Peto","year":"1998","unstructured":"Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson\u2019s disease quality of life questionnaire and its associated measures. J Neurol. 1998;245(Suppl 1):S10\u20134.","journal-title":"J Neurol"},{"key":"2830_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease. Qual Life Res. 1995;4:241\u20138.","journal-title":"Qual Life Res"},{"key":"2830_CR16","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18:e1003583.","journal-title":"PLoS Med"},{"key":"2830_CR17","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Second edition. Hoboken: Wiley; 2019.","DOI":"10.1002\/9781119536604"},{"key":"2830_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"2830_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455\u201363.","journal-title":"Biometrics"},{"key":"2830_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40035-016-0059-z","volume":"5","author":"S Chen","year":"2016","unstructured":"Chen S, Chan P, Sun S, Chen H, Zhang B, Le W, et al. The recommendations of Chinese Parkinson\u2019s disease and movement disorder society consensus on therapeutic management of Parkinson\u2019s disease. Transl Neurodegener. 2016;5:12.","journal-title":"Transl Neurodegener"},{"key":"2830_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/DDDT.S112723","volume":"11","author":"Y Wang","year":"2017","unstructured":"Wang Y, Sun SG, Zhu SQ, Liu CF, Liu YM, Di Q, et al. Analysis of pramipexole dose-response relationships in Parkinson\u2019s disease. Drug Des Devel Ther. 2017;11:83\u20139.","journal-title":"Drug Des Devel Ther"},{"key":"2830_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.0b013e31822affb0","volume":"77","author":"W Poewe","year":"2011","unstructured":"Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, et al. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77:759\u201366.","journal-title":"Neurology"},{"key":"2830_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77:767\u201374.","journal-title":"Neurology"},{"key":"2830_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mds.23396","volume":"26","author":"K Kieburtz","year":"2011","unstructured":"Kieburtz K. Twice-daily, low-dose pramipexole in early Parkinson\u2019s disease: a randomized, placebo-controlled trial. Mov Disord. 2011;26:37\u201344.","journal-title":"Mov Disord"},{"key":"2830_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6:513\u201320.","journal-title":"Lancet Neurol"},{"key":"2830_CR26","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.23590","volume":"26","author":"C Sampaio","year":"2011","unstructured":"Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, et al. Pardoprunox in early Parkinson\u2019s disease: results from 2 large, randomized double-blind trials. Mov Disord. 2011;26:1464\u201376.","journal-title":"Mov Disord"},{"key":"2830_CR27","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","volume":"12","author":"AH Schapira","year":"2013","unstructured":"Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson\u2019s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12:747\u201355.","journal-title":"Lancet Neurol"},{"key":"2830_CR28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.26941","volume":"32","author":"CW Olanow","year":"2017","unstructured":"Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, et al. A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson\u2019s disease. Mov Disord. 2017;32:783\u20139.","journal-title":"Mov Disord"},{"key":"2830_CR29","doi-asserted-by":"crossref","first-page":"300060520922449","DOI":"10.1177\/0300060520922449","volume":"48","author":"J Huang","year":"2020","unstructured":"Huang J, Hong W, Yang Z, Ding J, Ren Y. Efficacy of pramipexole combined with levodopa for Parkinson\u2019s disease treatment and their effects on QOL and serum TNF-\u03b1 levels. J Int Med Res. 2020;48:300060520922449.","journal-title":"J Int Med Res"},{"issue":"13","key":"2830_CR30","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/mds.23834","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, et al. Health-related quality-of-life scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord. 2011;26(13):2371\u201380. https:\/\/doi.org\/10.1002\/mds.23834.","journal-title":"Mov Disord"},{"key":"2830_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/mds.25664","volume":"29","author":"GW Duncan","year":"2014","unstructured":"Duncan GW, Khoo TK, Yarnall AJ, O\u2019Brien JT, Coleman SY, Brooks DJ, et al. Health-related quality of life in early Parkinson\u2019s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29:195\u2013202.","journal-title":"Mov Disord"},{"key":"2830_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.parkreldis.2018.06.034","volume":"56","author":"A Margolius","year":"2018","unstructured":"Margolius A, Cubillos F, He Y, Wu S, Schmidt P, Simuni T. Predictors of clinically meaningful change in PDQ-39 in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2018;56:93\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"2830_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score. Age Ageing. 1997;26:353\u20137.","journal-title":"Age Ageing"},{"key":"2830_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/ageing\/30.4.299","volume":"30","author":"V Peto","year":"2001","unstructured":"Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson\u2019s disease questionnaire. Age Ageing. 2001;30:299\u2013302.","journal-title":"Age Ageing"},{"key":"2830_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jclinepi.2016.11.016","volume":"82","author":"F Angst","year":"2017","unstructured":"Angst F, Aeschlimann A, Angst J. The minimal clinically important difference raised the significance of outcome effects above the statistical level, with methodological implications for future studies. J Clin Epidemiol. 2017;82:128\u201336. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.11.016.","journal-title":"J Clin Epidemiol"},{"key":"2830_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.gerinurse.2017.09.001","volume":"39","author":"SJ Lee","year":"2018","unstructured":"Lee SJ, Kim SR, Chung SJ, Kang HC, Kim MS, Cho SJ, et al. Predictive model for health-related quality of life in patients with Parkinson\u2019s disease. Geriatr Nurs. 2018;39:204\u201311.","journal-title":"Geriatr Nurs"},{"key":"2830_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2010.08.012","volume":"17","author":"SE Soh","year":"2011","unstructured":"Soh SE, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson\u2019s disease: a systematic review. Parkinsonism Relat Disord. 2011;17:1\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"2830_CR38","doi-asserted-by":"publisher","first-page":"e46327","DOI":"10.1371\/journal.pone.0046327","volume":"7","author":"IJ Higginson","year":"2012","unstructured":"Higginson IJ, Gao W, Saleem TZ, Chaudhuri KR, Burman R, McCrone P, et al. Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS ONE. 2012;7:e46327.","journal-title":"PLoS ONE"},{"issue":"653\u20139","key":"2830_CR39","first-page":"776","volume":"23","author":"C Marras","year":"2008","unstructured":"Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE. Predictors of deterioration in health-related quality of life in Parkinson\u2019s disease: results from the DATATOP trial. Mov Disord. 2008;23(653\u20139):776.","journal-title":"Mov Disord"},{"key":"2830_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/2047-9158-3-11","volume":"3","author":"Y Wang","year":"2014","unstructured":"Wang Y, Sun S, Zhu S, Liu C, Liu Y, Di Q, et al. The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson\u2019s disease: a randomized, double-blind, double-dummy, parallel-group study. Transl Neurodegener. 2014;3:11.","journal-title":"Transl Neurodegener"},{"key":"2830_CR41","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/ene.13106","volume":"23","author":"R Erro","year":"2016","unstructured":"Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Santangelo G, et al. The non-motor side of the honeymoon period of Parkinson\u2019s disease and its relationship with quality of life: a 4-year longitudinal study. Eur J Neurol. 2016;23:1673\u20139.","journal-title":"Eur J Neurol"},{"key":"2830_CR42","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/ene.12950","volume":"23","author":"KM Prakash","year":"2016","unstructured":"Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK. The impact of non-motor symptoms on the quality of life of Parkinson\u2019s disease patients: a longitudinal study. Eur J Neurol. 2016;23:854\u201360.","journal-title":"Eur J Neurol"},{"key":"2830_CR43","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/1531-8257(200011)15:6<1112::AID-MDS1008>3.0.CO;2-A","volume":"15","author":"A Schrag","year":"2000","unstructured":"Schrag A, Jahanshahi M, Quinn N. How does Parkinson\u2019s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord. 2000;15:1112\u20138.","journal-title":"Mov Disord"},{"key":"2830_CR44","volume-title":"The Parkinson\u2019s Disease Questionnaires User Manual (PDQ-39, ePDQ, PDQ-8, PDQ Summary Index, PDQ-Carer & PDQ-Carer Summary Index)","author":"C Jenkinson","year":"2018","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Dummett S, Kelly L, Morley D. The Parkinson\u2019s Disease Questionnaires User Manual (PDQ-39, ePDQ, PDQ-8, PDQ Summary Index, PDQ-Carer & PDQ-Carer Summary Index). 4th ed. Health Services Research Unit: University of Oxford; 2018.","edition":"4"},{"key":"2830_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1212\/WNL.49.1.162","volume":"49","author":"A Lieberman","year":"1997","unstructured":"Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson\u2019s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162\u20138.","journal-title":"Neurology"},{"key":"2830_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573\u201380.","journal-title":"Lancet Neurol"},{"key":"2830_CR47","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2147\/DDDT.S160300","volume":"12","author":"W Xiang","year":"2018","unstructured":"Xiang W, Sun YQ, Teoh HC. Comparison of nocturnal symptoms in advanced Parkinson\u2019s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des Devel Ther. 2018;12:2017\u201324.","journal-title":"Drug Des Devel Ther"},{"key":"2830_CR48","first-page":"707","volume":"4","author":"O Kano","year":"2008","unstructured":"Kano O, Ikeda K, Kiyozuka T, Iwamoto K, Ito H, Kawase Y, et al. Beneficial effect of pramipexole for motor function and depression in Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2008;4:707\u201310.","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02830-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02830-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02830-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T15:31:24Z","timestamp":1727883084000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02830-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2830"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02830-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ZZ was an employee of Boehringer Ingelheim during the conduct of the research; ML is a current employee. TL, SZ and ZL declare no conflict of interest regarding the publication of this paper. The author(s) meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors received no direct compensation related to the development of the manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"320"}}